全球首个PD-L1 ADC启动III期临床

医药魔方
Aug 28, 2025

8月27日,全球临床试验收录网站显示,辉瑞启动了PD-L1 ADC药物PF-08046054(SGN-PDL1V)的首个III期临床试验。该药物是首个进入III期阶段的PD-L1 ADC。该研究是一项随机、开放标签临床试验(n=680),旨在评估PF-08046054对比多西他赛治疗既往接受过治疗的PD-L1阳性非小细胞肺癌(NSCLC)患者的有效性和安全性。研究的主要终点是总生存期(OS)和无...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10